IDEMIA Announces a Change in Its Top Management Team, with a View to Building on Its Global Leadership in Augmented Identity
Didier LAMOUCHE, CEO of IDEMIA, today announced the appointment of two new members of IDEMIA’s Executive Committee. Philippe BARREAU (formerly MD of SICPA SA, a Swiss company providing secured identification and authentication solutions and services) will head up both the Citizen Identity and Public Security business units as Group Executive Vice-President, while Ed CASEY (former Chief Operating Officer of Serco, a UK-based global provider of public services in various areas, including citizen services) is appointed CEO of the Noram Identity & Security business unit.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180110005554/en/
Pierre BARRIAL (who was running the Mobile Operators business) is appointed Group Executive Vice-President of the Financial Institutions business unit. He has a successful record of accomplishment in managing organizations in challenging technology environments across multiple companies.
Fabien JAUTARD, who was previously managing the Mobile Operators activity in the Asia Pacific Region, replaces Pierre BARRIAL as Executive Vice-President of the Mobile Operators business unit. Fabien JAUTARD will also join IDEMIA’s Executive Committee.
IDEMIA currently operates in 180 countries, where it employs 14,000 people. In an ever more competitive market, the firm has also decided to strengthen its regional structure and has appointed new Presidents in charge of two regions. Eric DUFOREST, previously in charge of driving the global Financial Institutions activity, will now manage the Asia-Pacific Region. His recent success heading IDEMIA’s Financial Institutions business for five years makes Eric DUFOREST the ideal candidate to lead the group growth effort in the APAC Region. Marcello BELLINI, in charge of the Financial Institutions operations in Latin America, will also take the role as of now of President of the Latin America Region.
Philippe D'ANDREA is appointed European region President on top of his duties as Global Operations manager. His role will be to roll out and communicate the group strategy throughout the Region.
All the above appointments take effect immediately.
The result of the coming together, in May 2017, of OT (Oberthur Technologies) and Safran Identity & Security (Morpho), the new IDEMIA identity was unveiled on 28th September 2017. It is the global leader in Augmented Identity for an increasingly digital world, with a view to provide citizens and consumers with end-to-end full-secured solutions, when they interact, pay, connect, travel and vote.
IDEMIA will also continue to invest in R&D to develop high-tech future game-changing innovations and solutions amounting to €1bn over five years, by tapping into the strengths and know-how of the two companies that formed IDEMIA, while serving both public and private sector customers.
Didier LAMOUCHE, CEO of IDEMIA group, declared: “The strategic intent behind the creation of IDEMIA is to offer to the world state-of-the-art security solutions together with biometric-based convenience. The new management team is composed of talented and skilled leaders, coming from various horizons, who will be capable to deliver upon this vision and address and anticipate our clients’ needs worldwide.”
Additional Information about Philippe Barreau
Before joining IDEMIA, Mr. Barreau worked for SICPA SA, a growing Swiss company providing security features and systems as well as secured identification and authentication solutions and services, mostly to Governmental organizations. Mr. Barreau started in the division Security Inks as Regional Director in Switzerland and then became its global Sales and Marketing Director, before being appointed as Managing Director of Security Inks and Solutions Division.
Mr. Barreau has more than 25 years of experience in Finance, Sales, Marketing and General Management and occupied leading positions in international companies based in various countries, notably in Asia and Europe.
Mr. Barreau’s deep understanding of public markets, as well as his experience in managing a technologically driven company, will be essential in managing the joint growth of the Citizen Identity and Public Security business units of IDEMIA.
Additional Information about Ed Casey
Before joining IDEMIA, Mr. Casey spent 13 years within Serco Group plc, a leading provider of public services in defense, transport, immigration, healthcare and other citizen services. He held various senior management positions at Serco, including Group Chief Operating Officer and Member of the Board of Directors, Acting Group Chief Executive Officer, and Chief Executive Officer of Serco's Americas Division. Under Mr. Casey's leadership, the Americas business tripled in size and successfully integrated two acquisitions: RCI and SI International.
Prior to Serco, Mr. Casey held senior management positions in the energy, investment banking and private equity fields at NP Energy Inc., an energy marketing business he founded and later sold; Tenneco Energy; LG&E Energy Corp.; The Blackstone Group; and Fremont Group LLC.
Mr. Casey’s experience in IT value added services and in the public sector will be instrumental in supporting IDEMIA’s government clients in the USA and Canada in their digital transformation.
OT-Morpho is now IDEMIA, the global leader in Augmented Identity for an increasingly digital world, with the ambition to empower citizens and consumers alike to interact, pay, connect, travel and vote in ways that are now possible in a connected environment.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, we reinvent the way we think, produce, use and protect this asset, whether for individuals or for objects. We ensure privacy and trust as well as guarantee secure, authenticated and verifiable transactions for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
With close to $3 billion in revenues, IDEMIA is the result of the coming together of OT (Oberthur Technologies) and Safran Identity & Security (Morpho). With 14,000 employees around the world of more than 80 nationalities, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter
Hanna Sebbah, +33 (0)6 63 73 30 30
Manon Gaudefroy, 33 (0)6 85 30 60 02
Alisa Gribe-Marquis, T+33 (0)6 03 12 93 13
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Rimini Street Launches New Solutions that Further Extend the Life and Value of Enterprise Software as a Foundation for Innovation24.4.2018 16:00 | Pressemelding
Rimini Street, Inc . (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced the first offerings in a family of solutions designed to provide improved competitive advantage to organizations with mature and valuable enterprise software investments that can be used as a foundation for innovation. Rimini Street’s new solutions can enable an organization to quickly and cost-effectively modernize their current enterprise software with the latest desired features and capabilities, future-proof their technical platforms against yet-unknown technology changes, and secure their systems against a constantly evolving threat environment. Rimini Street’s new solutions enable organizations to leverage their existing systems as a solid foundation for an innovative hybrid IT strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/
Novaliq to Present Scientific and Clinical Research During the 2018 Association for Research in Vision and Ophthalmology Meeting in Honolulu, HI24.4.2018 15:53 | Pressemelding
Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced that four scientific posters will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Meeting in Honolulu, HI (April 29-May 3). The variety of data to be presented reflects Novaliq’s dedication to science and clinical research. With the collection of posters, Novaliq will share clinical and pre-clinical data on its EyeSol® drug delivery technology and provide insights into the mode of action of its NOV03/NovaTears® water-free therapy for the treatment of dry eye disease (DED). Furthermore, Novaliq will present its first pre-clinical efficacy data in glaucoma. Scientific posters supported by Novaliq will include: “Influence of perfluorohexyloctane containing eye drops on tear film thickness in patients with mild to moderate dry eye disease.” Authors: Garhöfer G., Schm
Temasys Communications and Appian Partner to Power Real-Time Communications in the Contact Center24.4.2018 15:00 | Pressemelding
Temasys Communications announced today that Appian has integrated with the Temasys Skylink technology, enabling real-time communications, including chat and co-browsing, in Appian’s new Intelligent Contact Center (ICC) Platform. “For our contact center customers, omni-channel communications are essential. Appian is working with Temasys to provide contact centers with real-time communication channels such as chat and co-browsing via the Temasys versatile SDKs,” said Arturo Oliver, Senior Director of Product Strategy at Appian. Temasys Skylink APIs will be compatible with the Appian Intelligent Contact Center Platform, making it easy for Appian customers to add real-time communication to their applications, including chat, voice, video and co-browsing. These integrations enable users to visit a website, begin a chat session that seamlessly escalates to a voice call and extend to co-browsing — all without changing apps or establishing a new connection. “We’re thrilled to work with Appian
PPG Reports Sustainability Progress, New 2025 Goals24.4.2018 13:07 | Pressemelding
PPG (NYSE:PPG) today released its 2017 Corporate Sustainability Report, which details the company’s continued progress in strengthening its sustainable operations in 2017 and the launch of new, aggressive sustainability goals it aims to achieve by 2025. The report is available at sustainability.ppg.com. “PPG’s sustainability efforts go beyond product innovations to extend to our customers’ operations and the communities in which we operate,” said Mark Cancilla, PPG vice president, environment, health and safety. “We are encouraged by our progress in 2017 and excited about our new goals, which are representative of the challenges and opportunities of our current business portfolio.” The company achieved the following progress in 2017: 32 percent of sales from products that provide customers with a sustainable advantage, an increase of 60 percent since 2012. This includes the unveiling of multiple products that provide a sustainable solution, such as Sigma Air Pure, a revolutionary bio-b
Bioiberica Approves Its Combined Drug for Osteoarthritis in Five More European Countries24.4.2018 12:17 | Pressemelding
Bioiberica's combination of chondroitin sulphate and glucosamine hydrochloride, a slow action drug to treat osteoarthritis symptoms, was approved as an ethical drug in France, Austria, Hungary, Poland, and Finland through a mutual recognition process from Spain. ‘This approval confirms that Drug Agencies from different countries attest to the effectiveness and safety of the combination of pharmaceutical grade chondroitin sulphate and glucosamine hydrochloride. This drug has proven to reduce pain and improve mobility in people affected by knee osteoarthritis which, due to its safety profile, could also be used as an alternative by those patients with cardiovascular or gastrointestinal problems who should not be prescribed anti-inflammatory drugs chronically’, stated Dr Juan Gispert, Bioiberica's R&D director. The principle study that guarantees its effectiveness is the MOVES clinical trial, published in the Annals of the Rheumatic Diseases, which concludes that the combination of chondr
Asuragen to Present at World CB & CDx Europe Summit in London, UK24.4.2018 12:00 | Pressemelding
Asuragen, Inc., a molecular diagnostics company delivering easy to use products for complex testing in genetics and oncology, announced that its senior vice president of commercial operations, Colin Hill, will chair a roundtable discussion during the 2018 World Clinical Biomarkers & Companion Diagnostic (CB & CDx) Europe Summit taking place May 1-3 in London, UK. The session will focus on the imminent changes to the regulatory environment in Europe and the implications for pharmaceutical and diagnostic companies collaborating to advance precision medicine. “Precision medicine is becoming a reality around the world, and the regulations that guide it are rapidly evolving,” said Hill. “It is essential that we build close collaboration between the pharmaceutical, medical device and in vitro diagnostics industry if we are going to successfully navigate this new environment. While our success will definitely leverage learnings from the US experience, we will have to broaden our thinking as w